Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (28)

2024

  1. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 10-15

  2. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  3. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

  4. Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change

    Journal of Clinical Medicine, Vol. 13, Núm. 17

2023

  1. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study

    The Lancet Neurology, Vol. 22, Núm. 12, pp. 1150-1159

  2. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

2022

  1. MNCD: A New Tool for Classifying Parkinson’s Disease in Daily Clinical Practice

    Diagnostics, Vol. 12, Núm. 1

  2. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy

    Epilepsy and Behavior, Vol. 137

2021

  1. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  2. Present and future of parkinson’s disease in Spain: Parkinson-2030 delphi project

    Brain Sciences, Vol. 11, Núm. 8

  3. The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish

    Headache, Vol. 61, Núm. 9, pp. 1403-1410

2020

  1. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

  2. RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases

    Neuro-Oncology Advances, Vol. 2, Núm. 1

2018

  1. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

    Revista Clinica Espanola, Vol. 218, Núm. 7, pp. 327-335

  2. Seizure-susceptible brain regions in glioblastoma: identification of patients at risk

    European Journal of Neurology, Vol. 25, Núm. 2, pp. 387-394

2017

  1. Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain

    Revista de Neurologia, Vol. 65, Núm. 8, pp. 361-367

  2. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure

    Acta Neurologica Scandinavica, Vol. 136, Núm. 3, pp. 254-264

  3. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study

    Epilepsy and Behavior, Vol. 73, pp. 173-179

2016

  1. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3

2015

  1. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: Identification of common and distinct olfactory targets across Alzheimer-related co-pathologies

    Oncotarget, Vol. 6, Núm. 37, pp. 39437-39456